REGIONAL> Development
Chengdu Academic Forum of Gastric Surgery a success
By Li Xin (China Daily Chongqing Bureau)
Updated: 2009-07-27 15:33

The "Academic Forum of Gastric Surgery 2009", co-sponsored by the Chinese Anti-Cancer Association of the Professional Committee of Gastric Cancer, was held in Chengdu, Sichuan province, on July 25, 2009.

The "Chinese Bases and Clinical Journal", "Chinese Medical Journal" Editorial Board, and the Gastrointestinal Surgery Department at the West China Hospital of Sichuan University were also involved. The forum was launched in an effort to promote the standardization of surgical treatment of gastric cancer, which affects a high percentage of the Chinese population.

The forum was successfully carried out with the help of noted surgical experts, who organized the forum as well as acted as consultants. The well-known gastric cancer treatment experts introduced the latest improvements in the surgical treatment of gastric cancer and presented key skills in laparoscopic gastric cancer surgery, as well as progress in gastric cancer treatment.

Professor Chen Zhixi, from the Gastrointestinal Surgery Department at the West China Hospital of Sichuan University, held a seminar on revolutionary breakthroughs in lymph node dissection using Nano-Carbon Suspension Injection in gastric surgery, which prompted lively discussion in experts present.

Nano-Carbon Suspension Injection is a local injection with lymphatic targeting agents. When injected into tumor tissue, it rapidly results in lymphatic drainage of the tumor.

The new technique can help physicians identify sentinel lymph nodes in tumors and regional drainage channels, helping determine the size and scope of the required lymphadenectomy, reduce tissue damage, and decrease the relapse rate of tumors.

It can also be used in lymphatic chemotherapy for malignant tumors. Latest research shows Nano-Carbon Suspension Injection which has absorbed chemotherapeutic drugs has a clear synergy to conventional chemotherapy.

Nano-Carbon Suspension Injection is the first patented product developed by Chongqing Laimei Pharmaceutical Co, Ltd, who has worked on it for 10 years. "The company from its inception decided to build a technology platform to conduct research and make developments on targeted drugs that can inhibit malignant tumors, and one of its key tasks is to study and produce targeted anti-cancer drugs that can inhibit the hyperplasia of the vascular system in malignant tumors," a company spokesperson said.

Normative surgical treatment of gastric cancer will benefit a large number of gastric cancer patients in the country, the spokesman added.